Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant in Migraine Prevention in Adolescents with Chronic Migraine
NCT06616194Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2024
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Rimegepant with Placebo (2 arms). Primary endpoint: Number of migraine days per month at 12 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
rimegepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT06616194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616194.